Literature DB >> 33010821

Diabetes, like COVID-19, is a wicked problem.

David Kerr1, Namino Glantz2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33010821      PMCID: PMC7529400          DOI: 10.1016/S2213-8587(20)30312-0

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


× No keyword cloud information.
Diabetes has long been mistaken as a tame problem. Following a recipe, playing chess, and doing open-heart surgery are tame problems. Tame problems can be solved by having engineers, clinicians, and scientists develop guidelines, algorithms, and systems that achieve easily measured outcomes that matter to these same stakeholders. For example, the longstanding and accepted approach in diabetes has been to empower experts to create algorithms, therapies, technologies, and models to manage glucose within controlled conditions, which are then offered to people with diabetes and their clinicians. Invariably, there is little effort to understand much about the anticipated users beyond their biology. This quantified approach also mistakenly assumes that if a variable cannot be measured, it is probably not important. These attempts to solve the problem of diabetes have, so far, been authoritative (eg, authorising self-proclaimed experts to develop clinical guidelines that are assumed to be adopted widely, or economic rationing of access to new devices and therapies by payers) or on the basis of free-market competition (eg, allowing pharmaceutical and medical device industries to develop independent approaches without collaboration). Needless to say, diabetes has not been solved, and that is because diabetes is not a tame problem. Diabetes, like COVID-19, is a wicked problem. The concept of a wicked problem arose in the 1960's, based on the realisation that purely scientific solutions to societal problems are doomed to fail. Wicked problems are impossible to solve because of contradictory and changing requirements, the absence of equality, and ever-evolving social complexities. Poverty, crime, and climate change are wicked problems. COVID-19 is also a classic wicked problem, as evidenced by the unanticipated and disproportionate effect of the virus on minority racial and ethnic populations and individuals who have experienced health disparities. A wicked problem persists in perpetuity because of incomplete information, multiple (often selfish) stakeholder interests, a large economic burden, and a ripple effect whereby every action triggers a reaction with other wicked problems. For example, during the COVID-19 pandemic, the exclusion of undocumented residents from the funding given to US taxpayers by the federal government reduced their purchasing power amid a looming recession, contributing further to both the public health and economic crises in US states such as California. COVID-19 is also a wicked problem for telehealth. COVID-19 has caused us to move away from in-person healthcare toward virtual visits. However, for telehealth to be successful, it is important that people have access to the technology required for virtual visits. In reality, in the USA one in four adults with Medicare do not have digital access (whether via a desktop or laptop computer with a high-speed internet connection, or via a smartphone with a wireless data plan) at home, making it unlikely that these people can participate in telehealth video visits with doctors. The proportion of people without digital access is notably higher among people of colour than among other populations. As the COVID-19 example shows, there is no single, correct, definite answer to a wicked problem. A wicked problem cannot be solved, merely resolved. When considering diabetes as a wicked problem, the aim should be a resolution with the least bad outcome for the majority. Now there are efforts to personalise diabetes care, allowing for the categorisation of subpopulations on the basis of biological and genetic variables. This approach allows identification of clusters of people with different characteristics and risks that could be responsive to targeted therapeutic interventions. However, beyond using genetic and biological factors to identify these subgroups, it is now recognised that sociocultural influences are also important factors in determining risk of progression of diabetes. People with diabetes vary psychosocially, not just biologically, and this should be reflected in the development of new technologies and approaches to the delivery of diabetes care. In other words, to resolve diabetes as a problem, social and biological influences should be integrated within technological developments and regulatory processes to create compassionate technology: technology that benefits the majority by focusing on the uniqueness of individuals. There is a need to create a digital diabetes ecosystem that is equitable. A digital diabetes ecosystem that can help to resolve diabetes as a wicked problem ideally should connect personal consumer (eg, food choices), physiological (eg, sleep patterns), behavioral (eg, physical activity), psychological (eg, mood), environmental (eg, air quality), and genetic data with an understanding of social preferences (eg, family meals vs eating alone). This ecosystem should both be integrated with clinician workloads and have empathy with the user. Creating an ecosystem will be an obstinate task, given that personal goals vary among individuals, and shift with time owing to the ripple effect of other wicked problems. Finding the problem centre (ie, a modifiable driver of the problem), and choosing the type and timing of an intervention, can be challenging. Technologies should be adaptive, adaptable, and affordable, both in terms of financial cost and personal burden for the user. Primary care physicians already understand that diabetes is a wicked problem, and that data and algorithms alone are insufficient. For scientists and engineers, illness affects the human condition in ways that can be frustratingly illogical and unpredictable. Machines can be created to provide sincerity, but without compassion and empathy, their value for providing human-like interactions is markedly low. Good clinicians are skilled at locating problems by finding where in a causal network the trouble truly lies and deciding what actions will actually work, thereby narrowing the gap between what is and what ought to be—the essence of addressing a wicked problem. That is also the challenge, and opportunity, for the diabetes community.
  7 in total

Review 1.  Quality of Evidence Supporting the Role of Tripterygium Glycosides for the Treatment of Diabetic Kidney Disease: An Overview of Systematic Reviews and Meta-Analyses.

Authors:  Hongshuo Shi; Pin Deng; Chengda Dong; Rongchen Lu; Guomin Si; Tiantian Yang
Journal:  Drug Des Devel Ther       Date:  2022-05-31       Impact factor: 4.319

2.  Clouds and Silver Linings: COVID-19 Pandemic Is an Opportune Moment to Democratize Diabetes Care Through Telehealth.

Authors:  David Kerr; Hope Warshaw
Journal:  J Diabetes Sci Technol       Date:  2020-10-13

3.  The Impact of Racial and Ethnic Health Disparities in Diabetes Management on Clinical Outcomes: A Reinforcement Learning Analysis of Health Inequity Among Youth and Young Adults in the SEARCH for Diabetes in Youth Study.

Authors:  Anna R Kahkoska; Teeranan Pokaprakarn; G Rumay Alexander; Tessa L Crume; Dana Dabelea; Jasmin Divers; Lawrence M Dolan; Elizabeth T Jensen; Jean M Lawrence; Santica Marcovina; Amy K Mottl; Catherine Pihoker; Sharon H Saydah; Michael R Kosorok; Elizabeth J Mayer-Davis
Journal:  Diabetes Care       Date:  2022-01-01       Impact factor: 17.152

4.  Dysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: Insights from continuous glucose monitoring.

Authors:  Souptik Barua; Ashutosh Sabharwal; Namino Glantz; Casey Conneely; Arianna Larez; Wendy Bevier; David Kerr
Journal:  EClinicalMedicine       Date:  2021-04-25

5.  A persisting parallel universe in diabetes care within America's capital.

Authors:  David Kerr; McKenna Aram; Keesha M Crosby; Namino Glantz
Journal:  EClinicalMedicine       Date:  2021-12-24

6.  Exploring the Molecular Mechanism of Liuwei Dihuang Pills for Treating Diabetic Nephropathy by Combined Network Pharmacology and Molecular Docking.

Authors:  Gaoxiang Wang; Lin Zeng; Qian Huang; Zhaoqi Lu; Ruiqing Sui; Deliang Liu; Hua Zeng; Xuemei Liu; Shufang Chu; Xinhui Kou; Huilin Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-13       Impact factor: 2.629

7.  Diabetes Technology Meeting 2020.

Authors:  Trisha Shang; Jennifer Y Zhang; B Wayne Bequette; Jennifer K Raymond; Gerard Coté; Jennifer L Sherr; Jessica Castle; John Pickup; Yarmela Pavlovic; Juan Espinoza; Laurel H Messer; Tim Heise; Carlos E Mendez; Sarah Kim; Barry H Ginsberg; Umesh Masharani; Rodolfo J Galindo; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2021-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.